A vs GEHC

Agilent Technologies exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust accounting strength, and solid profitability metrics including an ROE of 20.62% and operating margin of 26.38%. The company is growing revenue and earnings at double-digit rates, supported by consistent earnings beat rates and strong cash flow generation, though key financial data like Altman Z-Score and cash/debt figures are missing. However, the stock trades at a premium valuation (P/E of 30.28 vs sector average of 215 but with much lower growth than peers), and insider selling activity raises caution. While analysts are bullish with a $169.67 target price, the technical trend is bearish and recent price performance has been weak over the past year despite a short-term rebound.

GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.